0000000000591613

AUTHOR

Enrique Rodríguez

showing 5 related works from this author

Cell-free DNA and Microvascular Damage in ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.

2019

INTRODUCTION AND OBJECTIVES Cell-free DNA (cfDNA) in ST-segment elevation myocardial infarction might originate from hyperactivated leukocytes at the coronary lesion. Our aim was to investigate the relationship between cfDNA and coronary reperfusion. METHODS We studied 116 patients treated with primary angioplasty using thrombus aspiration. Coronary (during aspiration) and peripheral (at the end of the procedure) blood samples were drawn for cfDNA, as well as high-sensitivity troponin T and myeloperoxidase quantification. The primary endpoint was no ST-segment resolution (STR) (≥ 70%) and the secondary endpoint was lack of final Thrombolysis In Myocardial Infarction flow 3 (TIMI 3). RESULTS…

Malemedicine.medical_specialtymedicine.medical_treatmentMyocardial ReperfusionMyocardial Reperfusion Injury030204 cardiovascular system & hematologyLymphocyte ActivationLesion03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionTroponin TInternal medicinemedicineClinical endpointLeukocytesST segmentHumanscardiovascular diseasesMyocardial infarctionProspective StudiesPeroxidaseTroponin Tbusiness.industryPercutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedmedicine.diseaseTreatment OutcomeMicrovesselsCardiologyST Elevation Myocardial InfarctionFemalemedicine.symptombusinessCell-Free Nucleic AcidsTIMIRevista espanola de cardiologia (English ed.)
researchProduct

Similar Clinical Course and Significance of Circulating Innate and Adaptive Immune Cell Counts in STEMI and COVID-19

2020

This study aimed to assess the time course of circulating neutrophil and lymphocyte counts and their ratio (NLR) in ST-segment elevation myocardial infarction (STEMI) and coronavirus disease (COVID)-19 and explore their associations with clinical events and structural damage. Circulating neutrophil, lymphocyte and NLR were sequentially measured in 659 patients admitted for STEMI and in 103 COVID-19 patients. The dynamics detected in STEMI (within a few hours) were replicated in COVID-19 (within a few days). In both entities patients with events and with severe structural damage displayed higher neutrophil and lower lymphocyte counts. In both scenarios, higher maximum neutrophil and lower mi…

LymphocyteCelllcsh:MedicineseverityDiseaselymphocyte030204 cardiovascular system & hematologymedicine.disease_causeArticle03 medical and health sciences0302 clinical medicineImmune systemneutrophilsmedicinecardiovascular diseasesMyocardial infarction030304 developmental biologyCoronavirus0303 health sciencesbusiness.industrylcsh:RCOVID-19General Medicinemedicine.diseaseAcquired immune systemNeutrophiliamyocardial infarctionmedicine.anatomical_structureImmunologyprognosismedicine.symptombusinessJournal of Clinical Medicine
researchProduct

ADN libre y daño microvascular en el infarto agudo de miocardio con elevación del segmento ST tratado con intervención coronaria primaria

2019

Resumen Introduccion y objetivos En el infarto agudo de miocardio con elevacion del segmento ST, el ADN libre circulante podria originarse de los leucocitos activados en la lesion coronaria. El objetivo fue investigar la relacion entre el ADN libre y la reperfusion coronaria. Metodos Se incluyo a 116 pacientes, tratados con angioplastia primaria y tromboaspiracion. Se cuantifico el ADN libre coronario (durante la aspiracion) y periferico (al final del procedimiento), asi como la troponina T ultrasensible y la mieloperoxidasa. El objetivo primario fue la no resolucion del segmento ST (RST) (≥ 70%) y el secundario la ausencia de flujo Thrombolysis In Myocardial Infarction 3 (TIMI 3) final. Re…

03 medical and health sciences0302 clinical medicinebusiness.industryMedicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

Growth differentiation factor 15 and geriatric conditions in acute coronary syndrome

2019

Abstract Background Growth differentiation factor 15 (GDF-15) is a marker of cell senescence. Age is a well-known determinant of GDF-15 levels, yet no study has analyzed the relationship between geriatric conditions and GDF-15. We hypothesize that geriatric conditions reflecting biological age might be stronger determinants of GDF-15 than chronological age in elderly patients with acute coronary syndrome. Methods A total of 208 patients (mean age = 78.3 ± 7.0 years) were included. Prior to discharge, a thorough geriatric assessment was performed and GDF-15 measured. Predictors of GDF-15 (transformed by its natural logarithm) were determined with linear regression. Furthermore, Cox regressio…

MaleAcute coronary syndromemedicine.medical_specialtyGrowth Differentiation Factor 15Multivariate analysisRenal function030204 cardiovascular system & hematologyCohort Studies03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineAcute Coronary SyndromeGeriatric AssessmentAgedKillip classAged 80 and overProportional hazards modelbusiness.industryHazard ratiomedicine.diseaseComorbidityPatient DischargeConfidence intervalembryonic structuresFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesInternational Journal of Cardiology
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct